跳转至内容
Merck
CN

L8668

Sigma-Aldrich

左乙拉西坦

≥98% (HPLC)

登录查看公司和协议定价

别名:
(αS)-α-乙基-2-氧代-1-吡咯烷乙酰胺, 2(S)-(2-氧吡咯烷-1-基)丁酰胺
经验公式(希尔记法):
C8H14N2O2
分子量:
170.21
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white

溶解性

H2O: >5 mg/mL

创始人

UCB Inc.

SMILES字符串

CC[C@H](N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

InChI key

HPHUVLMMVZITSG-LURJTMIESA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

Levetiracetam is a member of the pyrrolidone family, which is a second-generation anti-epileptic drug (AED). It acts as a neuroprotective and hyperalgesic drug. Levetiracetam is implicated in cholinergic neurotransmission.

应用

Levetiracetam has been used as an anti-epileptic drug to study its effects on glucose-mediated death.

生化/生理作用

左乙拉西坦是一种具有抗癫痫活性的吡咯烷。左乙拉西坦的立体选择性结合仅限于中枢神经系统的突触质膜,而在周围组织中不发生立体选择性结合。左乙拉西坦在不影响正常神经元兴奋性的情况下抑制簇状放电,这表明它可以选择性地阻止癫痫样簇状放电的超同步和发作活动的传播。

特点和优势

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Shaikhah Alshuaib et al.
Synapse (New York, N.Y.), 74(8), e22154-e22154 (2020-03-20)
Levetiracetam (LEV) is a widely prescribed antiepileptic drug, but its actions on neuronal function are not fully characterized. Since this drug is believed to enter neurons by binding to a vesicular protein during endocytosis, we used motor axons of the
Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug
Cortes-Altamirano JL, et al.
Neurology India, 64(6), 1266-1266 (2016)
Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation
Wang A, et al.
Cell, 166(6), 1512-1525 (2016)
D Consoli et al.
Cerebrovascular diseases (Basel, Switzerland), 34(4), 282-289 (2012-11-07)
Strokes are the leading cause of epileptic seizures in adults and account for 50% of seizures in those over the age of 65 years. The use of antiepileptic drugs to prevent recurrent poststroke seizures is recommended. One hundred and twenty-eight
Hai-Dun Yan et al.
Brain research bulletin, 90, 142-148 (2012-10-31)
Levetiracetam (LEV) is a widely used antiepileptic agent for partial refractory epilepsy in humans. LEV has unique antiepileptic effects in that it does not inhibit electroshock- or pentylenetetrazol-induced convulsion, but does inhibit seizures in kindling animal and spontaneously epileptic rat

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门